The recombinant shingles vaccine links to a 9% lower cardiovascular disease burden in older adults over a seven-year period, according to large-scale electronic health record data. The finding provides new insight into potential non-infectious benefits of the immunization beyond preventing shingles and its common complication, postherpetic neuralgia.
Study Design and Electronic Health Record Data
Researchers analyzed patient records from the TriNetX US Collaborative Network, which covers approximately 60 healthcare organizations and includes data from more than 100 million patients, according to study documentation. The data modalities captured within the network comprise patient demographics, medical diagnoses coded via the International Classification of Diseases (ICD-10-CM), procedures, and laboratory measurements. Participating healthcare organizations typically contribute nine years of historical clinical data, ensuring a robust sample size for observational epidemiological analysis.
To evaluate causal inference, the study utilized an instrumental-variable framework where the timing of vaccination served as an instrument for the specific vaccine type received. Compliance with the vaccine allocation was high, with 93.5% of individuals in the 2018 cohort receiving the recombinant shingles vaccine, according to the methodology. This rigorous approach helps control for confounding variables while tracking long-term health outcomes across large patient populations.
Understanding Shingles and Vaccine Recommendations
Shingles, medically termed herpes zoster, manifests as a painful skin rash accompanied by blisters, fever, headache, chills, or upset stomach, according to the Vaccine Information Statement. The condition stems from the reactivation of the varicella-zoster virus—the same pathogen responsible for chickenpox—which remains dormant in the body after initial infection. The most frequent and debilitating complication of the disease is postherpetic neuralgia (PHN), a severe, long-lasting nerve pain occurring in previously affected areas.
The Vaccine Information Statement recommends the recombinant zoster vaccine as a two-dose series for adults aged 50 years and older, as well as for immunocompromised individuals aged 19 and older. Because the recombinant version contains no live virus, it can be safely administered to patients with varied health statuses, offering strong protection against the acute rash and its chronic neurological sequelae.
Common Vaccine Side Effects
Patients receiving the recombinant shingles vaccine frequently experience temporary side effects as the immune system responds to the immunization. According to the Vaccine Information Statement, a sore arm with mild to moderate pain, redness, and swelling is very common at the injection site. Systemic reactions such as tiredness, muscle pain, headache, shivering, fever, stomach pain, and nausea may also occur temporarily. These symptoms typically resolve on their own within two to three days without requiring medical intervention.
Frequently Asked Questions
- Who should receive the recombinant shingles vaccine? The Vaccine Information Statement recommends the vaccine for all adults aged 50 and older, as well as adults aged 19 and older who have weakened immune systems due to specific diseases or medical treatments.
- How many doses are required? The immunization is administered as a two-dose series. For most adults, the second dose is given two to six months after the initial dose.
- Can the vaccine cause shingles? No. The recombinant shingles vaccine does not contain any live virus, meaning it cannot cause shingles or chickenpox.
Related reading